<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313610</url>
  </required_header>
  <id_info>
    <org_study_id>DS11036</org_study_id>
    <nct_id>NCT02313610</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis</brief_title>
  <official_title>Efficacy and Safety of Qinbudan as an Adjunct Therapy in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Chinese medicine Qinbudan
      in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retreatment of tuberculosis involves the management of entities as diverse as relapse,
      failure, treatment after default, and poor patient adherence to the previous treatment. The
      emergence of conditions for selection of resistance (failure and partial abandonment) is a
      matter of great concern. The current chemotherapy is the primary interventions, but the
      long-term drug combination therapy often leads to adverse reactions. The purpose of this
      study that is to exploring the role of Chinese medicine Qinbudan on Patients who are
      initially sputum smear positive or culture-positive who have been treated previously for
      pulmonary tuberculosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time of sputum conversion between the 2 groups will be evaluated</measure>
    <time_frame>Measured during the 8 months treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of all pulmonary tuberculosis symptoms</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of chest X-ray changes of patients</measure>
    <time_frame>8 months to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell classification in peripheral blood</measure>
    <time_frame>8 months to baseline</time_frame>
    <description>immunologic function(CD3、CD4、CD8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rata</measure>
    <time_frame>once every month during the 8 months treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cure rate will be evaluated as the primary parameter of efficacy</measure>
    <time_frame>8-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relapse in patients of both groups will be compared</measure>
    <time_frame>at 12 months after the completion of the therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Qinbudan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program （2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan table, table, 4, thrice a day, 8 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Qinbudan Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program（2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan Placebo, table, 4, thrice a day, 8 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qinbudan</intervention_name>
    <description>Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice</description>
    <arm_group_label>Qinbudan</arm_group_label>
    <other_name>Qinbudan table</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qinbudan Placebo</intervention_name>
    <description>Qinbudan Placebo was the same as therapeutic drug in package,shape,size.</description>
    <arm_group_label>Control Qinbudan Placebo</arm_group_label>
    <other_name>Qinbudan table Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are initially sputum smear positive (at least two smears as &quot;1+&quot; or at
             least have a smear as &quot;2+&quot; and above) or culture-positive for pulmonary tuberculosis
             who have been treated previously

          -  Aged 18 -65 years of age

          -  Patients who are willing to give written informed consent

        Exclusion Criteria:

          -  Participation in another clinical trial 1 month prior to study entry

          -  Female patients in lactation period, pregnancy or planning to get pregnant during the
             trial

          -  Patients who are allergic to the therapeutic medicine

          -  Patients with severe primary diseases such as cancer, cardiovascular system, digestive
             system, kidney and hematopoietic system diseases

          -  Patients co-infected with HIV, hepatitis B or hepatitis C

          -  Patients with mental illness, acrasia

          -  Abnormal liver function or combined with other underlying liver disease (fatty liver,
             alcoholic liver)

          -  Patients with diabetes, Plasma glucose poorly controlled undertaking

          -  Patients with auditory dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guang Ji</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebei provincial chest hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan tuberculosis dispensary</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi provincial chest hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang chest hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uygur Autonomous Region of Xinjiang Chest Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830049</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing chest hospital,Capital medical university</name>
      <address>
        <city>Beijing</city>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 85th hospital of chinese people's liberation army</name>
      <address>
        <city>Shanghai</city>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai pulmonary hospital affiliated Tongji University</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen Donghu hospital</name>
      <address>
        <city>Shenzhen</city>
        <zip>518112</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Haihe hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300350</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2014</study_first_submitted>
  <study_first_submitted_qc>December 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2014</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retreatment Pulmonary Tuberculosis, Qinbudan,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

